RELATED CONTENT
NEWS
- Lawsuits and product recalls undermine J&J 2Q results
- Comparative efficacy should have a "formal role in drug licensing"
- Focus on Almirall: partnering, new products and mature markets are key targets
- US FDA approves flu vaccine formulations for 2011-12 season; firms start shipping

